ICU Medical, Inc. (NASDAQ:ICUI - Get Free Report) CEO Vivek Jain sold 1,373 shares of ICU Medical stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $155.48, for a total transaction of $213,474.04. Following the transaction, the chief executive officer now owns 104,593 shares in the company, valued at $16,262,119.64. The trade was a 1.30 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Vivek Jain also recently made the following trade(s):

NASDAQ ICUI traded up $2.81 during trading on Thursday, reaching $157.98. 208,164 shares of the company's stock were exchanged, compared to its average volume of 269,089. The firm has a market capitalization of $3.87 billion, a PE ratio of -34.57 and a beta of 0.62. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. The company's fifty day simple moving average is $164.91 and its 200-day simple moving average is $155.49. ICU Medical, Inc. has a fifty-two week low of $86.80 and a fifty-two week high of $196.26.

Large investors have recently made changes to their positions in the stock. Victory Capital Management Inc. raised its position in shares of ICU Medical by 2,966.3% during the second quarter. Victory Capital Management Inc. now owns 141,848 shares of the medical instruments supplier's stock valued at $16,844,000 after buying an additional 137,222 shares during the last quarter. Millennium Management LLC lifted its holdings in ICU Medical by 327.8% during the 2nd quarter. Millennium Management LLC now owns 136,070 shares of the medical instruments supplier's stock worth $16,158,000 after buying an additional 104,264 shares in the last quarter. FMR LLC grew its position in shares of ICU Medical by 2,676.6% during the 3rd quarter. FMR LLC now owns 104,094 shares of the medical instruments supplier's stock worth $18,968,000 after buying an additional 100,345 shares during the period. Granite Investment Partners LLC acquired a new position in ICU Medical in the second quarter valued at about $10,650,000. Finally, State Street Corp increased its position in shares of ICU Medical by 9.3% in the 3rd quarter. State Street Corp now owns 907,607 shares of the medical instruments supplier's stock valued at $165,384,000 after buying an additional 77,506 shares in the last quarter. Institutional investors own 96.10% of the company's stock.

ICUI has been the topic of several recent research reports. Raymond James boosted their price target on ICU Medical from $158.00 to $190.00 and gave the stock an "outperform" rating in a research report on Thursday, September 12th. Needham & Company LLC reissued a "hold" rating on shares of ICU Medical in a research report on Wednesday, November 13th. KeyCorp upped their price target on shares of ICU Medical from $198.00 to $209.00 and gave the company an "overweight" rating in a report on Wednesday, November 13th. StockNews.com upgraded ICU Medical from a "hold" rating to a "buy" rating in a research report on Wednesday, November 20th. Finally, Jefferies Financial Group upgraded shares of ICU Medical from a "hold" rating to a "buy" rating and set a $200.00 price objective on the stock in a research note on Wednesday, December 11th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $199.67.

View Our Latest Stock Report on ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider ICU Medical, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ICU Medical wasn't on the list.

While ICU Medical currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.